SWOT Analysis
- S
- W
- O
- T
-
Strength (12)
Strong Momentum: Price above short, medium and long term moving averages
-
Weakness (3)
Declining ROA
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (1)
See all stocks where MFs decreased their stake last quarter. MFs decreasing their shareholding in a stock is considered negative for the stock.
- Strong Momentum: Price above short, medium and long term moving averages
- Companies with high TTM EPS Growth
- New 52 week high today
- Growth in Net Profit with increasing Profit Margin (QoQ)
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Companies with Low Debt
- Increasing Revenue every Quarter for the past 4 Quarters
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Annual Net Profits improving for last 2 years
- Book Value per share Improving for last 2 years
- Companies with decreasing Promoter pledge
- RSI indicating price strength
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
EMA
SMA
- 5 Day 1,699.2
- 10 Day 1,685.9
- 12 Day 1,682.0
- 20 Day 1,668.7
- 26 Day 1,659.5
- 50 Day 1,623.6
- 100 Day 1,551.0
- 200 Day 1,443.6
1,713.40
-1.19%
Current Price
- Bullish Moving Averages 16
- Bearish Moving Averages 0
Resistance and support
1,719.57PIVOT
- First Resistance 1,732.7
- Second Resistance 1,752.1
- Third Resistance 1,765.2
- First Support 1,700.2
- Second Support 1,687.1
- Third Support 1,667.7
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 1.69%
- 3.80%
- 3.93%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 11,171.72 | 10,933.30 | 10,645.64 | 8,457.00 | 11,287.14 |
|
| Operating Profit | 3,074.56 | 2,557.57 | 2,224.04 | 1,489.85 | 1,398.69 |
|
| OP Profit Margin | 27.52 | 23.39 | 20.89 | 17.62 | 12.39 |
|
| Interest | 213.15 | 230.04 | 182.60 | 74.58 | 16.94 |
|
| Profit After Tax | 2,414.80 | 1,746.79 | 1,954.14 | 1,227.11 | 1,454.71 |
|
| Cash Profit | 2,683.71 | 2,062.73 | 2,252.94 | 1,486.15 | 1,944.68 |
|
| EPS | 41.58 | 30.08 | 33.35 | 20.94 | 24.83 |
|
- CAGR IN 10 YEARS
- 11.64%
- 3.84%
- 2.35%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 58.08 | 58.08 | 58.59 | 58.59 | 58.59 |
|
| Reserve Surplus | 22,659.61 | 20,476.03 | 19,664.23 | 17,975.44 | 17,058.75 |
|
| TOT Debts | 4,285.24 | 4,646.60 | 2,860.74 | 4,203.16 | 1,894.89 |
|
| Gross Block | 4,633.15 | 4,230.61 | 4,043.49 | 6,214.71 | 5,724.90 |
|
| Capital Work In Progress | 228.55 | 87.53 | 132.68 | 239.09 | 225.15 |
|
| Cash Liquid Investment | 162.50 | 298.36 | 94.34 | 373.41 | 50.78 |
|
| Net Working Capital | 5,092.40 | 5,410.34 | 4,714.70 | 7,230.67 | 7,251.41 |
|
| Current Assets | 7,336.69 | 7,741.26 | 7,286.57 | 10,020.22 | 9,878.92 |
|
| Current Liabilities | 2,244.29 | 2,330.92 | 2,571.87 | 2,789.55 | 2,627.51 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 2,799.51 | 2,786.55 | 2,747.28 | 2,789.72 | 2,848.17 |
|
| Gross Profit | 1,077.07 | 948.24 | 853.82 | 826.77 | 820.11 |
|
| Gross Profit Margins | 53.96 | 55.08 | 48.95 | 55.40 | 52.95 |
|
| Operating Profit | 882.25 | 781.42 | 772.10 | 724.70 | 796.34 |
|
| OP Profit Margin | 37.69 | 33.14 | 30.22 | 29.13 | 28.44 |
|
| Interest | 47.07 | 47.27 | 48.43 | 57.45 | 60.00 |
|
| Profit After Tax | 737.22 | 692.23 | 582.07 | 581.37 | 559.13 |
|
| Cash Profit | 806.21 | 764.16 | 653.99 | 652.86 | 629.15 |
|
| EPS | 12.75 | 11.92 | 10.02 | 10.10 | 9.63 |
|
- CAGR IN 10 YEARS
- 11.64%
- 3.84%
- 2.35%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 31.34 | 38.56 | 32.67 | 24.73 | 26.94 |
|
| P/BV | 3.33 | 3.28 | 3.24 | 1.68 | 2.29 |
|
| MCAP Sales | 6.78 | 6.16 | 6.00 | 3.59 | 3.47 |
|
| Asset Turnover | 0.43 | 0.46 | 0.47 | 0.41 | 0.58 |
|
| EV/EBITDA | 21.79 | 24.85 | 23.01 | 17.68 | 19.83 |
|
| DEBT/EQUITY | 0.21 | 0.19 | 0.19 | 0.17 | 0.18 |
|
| ROE | 11.17 | 8.68 | 10.35 | 6.98 | 8.81 |
|
| ROCE | 12.91 | 10.82 | 11.74 | 8.18 | 8.49 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceuticals company Aurobindo Pharma announced Q1FY27 results
Consolidated Financial Highlights:
- Revenue from Operations: Stood at Rs 91,503.5 million, representing a YoY growth of 16.3% compared to Rs 78,681.4 million in Q1FY26 and a QoQ increase of 3.35% from Rs 88,533.4 million in Q4FY26.
- Total Income: Reached Rs 94,145.8 million, up 18.08% YoY from Rs 79,734.4 million and up 4.95% QoQ from Rs 89,703.8 million.
- Profit Before Tax (PBT): Reported at Rs 15,150.9 million, an increase of 25.55% YoY from Rs 12,068.0 million and a growth of 17.4% QoQ from Rs 12,906.1 million.
- Profit After Tax (PAT): Net profit attributable to owners of the parent company was Rs 10,325.6 million, marking a YoY growth of 25.2% from Rs 8,247.5 million and a QoQ growth of 12.08% from Rs 9,212.6 million.
- Earnings Per Share (EPS): Basic and diluted EPS stood at Rs 17.86 for the quarter, compared to Rs 14.20 in Q1FY26 and Rs 15.86 in Q4FY26.
Standalone Financial Highlights:
- Revenue from Operations: Stood at Rs 27,995.1 million, reflecting a YoY decline of 1.71% from Rs 28,481.7 million, but a marginal QoQ increase of 0.47% from Rs 27,865.5 million in Q4FY26.
- Total Income: Reached Rs 30,414.0 million, up 3.73% YoY from Rs 29,319.4 million and up 1.36% QoQ from Rs 30,006.4 million.
- Profit Before Tax (PBT): Reported at Rs 10,080.8 million, an increase of 34.39% YoY from Rs 7,500.9 million and a growth of 15.04% QoQ from Rs 8,763.1 million.
- Profit After Tax (PAT): Net profit for the quarter was Rs 7,372.2 million, up 31.85% YoY from Rs 5,591.3 million and up 6.5% QoQ from Rs 6,922.3 million.
Business Highlights:
- US Revenue: Increased by 8.1% YoY to Rs 37,700 million, primarily driven by volume gains and new launches, and grew 6.4% QoQ from Rs 35,430 million.
- Europe Revenue: Grew significantly by 25.6% YoY to Rs 29,370 million, accounting for 32.1% of consolidated revenue, and grew 5.1% QoQ from Rs 27,950 million.
- Growth Markets Revenue: Saw a robust growth of 37.7% YoY to Rs 10,630 million and an 8.5% QoQ increase from Rs 9,800 million.
- ARV Revenue: Stood at Rs 3,300 million, a YoY decrease of 6.9% but a marginal QoQ increase of 0.8% compared to Q4FY26.
- Active Pharmaceutical Ingredients (API) Revenue: Grew by 14.6% YoY to Rs 10,490 million, although it saw a sequential QoQ decline of 13.1% from Rs 12,080 million due to seasonal softness in the antibiotics portfolio.
- Acquisitions & Buyback: The company completed the acquisition of 100% membership interest in Lannett Company LLC on June 29, 2026. Additionally, the company approved a buyback of equity shares for an aggregate value not exceeding Rs 8,000 million.
- Product Approvals: Received final approval for 10 products from USFDA during the quarter.
- Cash Flow: Generated free cash flow of USD 98 million during the quarter.
K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company, said: “We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio. While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long-term growth objectives and create sustained value for our stakeholders.”
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | 1,713.40 | 98,585.25 | 51.78 | 0.04 | 26.63 | Mar 2026 |
| Sun Pharmaceutical Industries Ltd | 1,868.90 | 448,411.71 | 13.36 | 0.05 | 36.99 | Mar 2026 |
| Divis Laboratories Ltd | 9,410.50 | 249,819.21 | 53.97 | 0.11 | 85.61 | Mar 2026 |
| Torrent Pharmaceuticals Ltd | 4,970.00 | 189,042.82 | 39.32 | 0.04 | 87.65 | Mar 2026 |
| Zydus Lifesciences Ltd | 1,161.00 | 115,810.19 | 10.80 | 0.07 | 25.23 | Mar 2026 |
| Cipla Ltd | 1,386.10 | 111,977.26 | -12.17 | 0.06 | 33.34 | Mar 2026 |
| Laurus Labs Ltd | 2,017.50 | 109,007.99 | 118.52 | 0.11 | 100.00 | Mar 2026 |
| Mankind Pharma Ltd | 2,437.80 | 100,692.13 | -7.60 | 0.06 | 48.54 | Mar 2026 |
| Dr Reddys Laboratories Ltd | 1,198.30 | 100,019.74 | -9.41 | 0.06 | 31.52 | Mar 2026 |
| Lupin Ltd | 2,124.50 | 97,146.13 | 3.81 | 0.04 | 17.46 | Mar 2026 |
| Glenmark Pharmaceuticals Ltd | 2,450.00 | 69,145.04 | 16.20 | 0.06 | 38.46 | Mar 2026 |
| Biocon Ltd | 395.00 | 64,372.92 | 7.22 | 0.08 | 154.30 | Mar 2026 |
| Alkem Laboratories Ltd | 5,364.00 | 64,134.67 | -2.11 | 0.04 | 29.02 | Mar 2026 |
| Abbott India Ltd | 26,960.00 | 57,290.00 | -12.72 | 0.05 | 35.49 | Mar 2026 |
| Anthem Biosciences Ltd | 917.45 | 51,683.48 | 7.05 | 0.09 | 89.86 | Mar 2026 |
| Ipca Laboratories Ltd | 2,008.20 | 50,948.88 | 49.78 | 0.07 | 37.05 | Mar 2026 |
| Gland Pharma Ltd | 2,940.20 | 48,516.49 | 45.81 | - | 43.00 | Mar 2026 |
| Glaxosmithkline Pharmaceuticals Ltd | 2,862.90 | 48,499.25 | 3.90 | 0.08 | 45.42 | Mar 2026 |
| Ajanta Pharma Ltd | 3,542.10 | 44,261.74 | 38.99 | 0.06 | 38.92 | Mar 2026 |
| J B Chemicals & Pharmaceuticals Ltd | 2,408.90 | 38,676.99 | 45.54 | 0.04 | 54.59 | Mar 2026 |
| Emcure Pharmaceuticals Ltd | 2,009.30 | 38,118.56 | 49.85 | 0.06 | 37.25 | Mar 2026 |
| Wockhardt Ltd | 2,187.30 | 35,541.91 | 43.29 | 0.17 | 85.86 | Mar 2026 |
| Sai Life Sciences Ltd | 1,608.00 | 34,156.85 | 79.74 | 0.07 | 94.41 | Mar 2026 |
| Neuland Laboratories Ltd | 22,610.00 | 29,008.38 | 42.44 | 0.12 | 58.25 | Mar 2026 |
| Piramal Pharma Ltd | 214.66 | 28,578.72 | 5.57 | 0.10 | -90.95 | Mar 2026 |
| Acutaas Chemicals Ltd | 3,425.70 | 28,046.59 | 132.88 | 0.13 | 72.34 | Mar 2026 |
| Granules India Ltd | 875.15 | 23,872.33 | 61.12 | 0.05 | 36.06 | Mar 2026 |
| Caplin Point Laboratories Ltd | 2,756.60 | 20,953.38 | 18.74 | 0.12 | 30.91 | Mar 2026 |
| Shilpa Medicare Ltd | 1,070.80 | 20,942.90 | 161.94 | 0.19 | 70.45 | Mar 2026 |
| Pfizer Ltd | 4,035.70 | 18,462.41 | -22.28 | 0.06 | 25.13 | Mar 2026 |
| OneSource Specialty Pharma Ltd | 1,599.20 | 18,338.49 | -14.02 | 0.15 | -377.39 | Mar 2026 |
| ERIS Lifesciences Ltd | 1,295.30 | 17,950.69 | -20.83 | 0.05 | 26.96 | Mar 2026 |
| Cohance Lifesciences Ltd | 460.45 | 17,616.69 | -49.55 | - | 301.05 | Mar 2026 |
| Alivus Life Sciences Ltd | 1,400.40 | 17,192.91 | 47.90 | - | 28.51 | Mar 2026 |
| Jubilant Pharmova Ltd | 1,049.25 | 16,714.55 | -5.91 | 0.07 | 47.57 | Mar 2026 |
| Alembic Pharmaceuticals Ltd | 848.75 | 16,683.30 | -11.34 | 0.07 | 24.24 | Mar 2026 |
| Astrazeneca Pharma India Ltd | 6,650.00 | 16,625.00 | -26.72 | 0.07 | 98.22 | Mar 2026 |
| Concord Biotech Ltd | 1,579.40 | 16,523.08 | -4.72 | - | 60.61 | Mar 2026 |
| Marksans Pharma Ltd | 338.10 | 15,321.47 | 89.55 | 0.14 | 29.40 | Mar 2026 |
| Natco Pharma Ltd | 816.30 | 14,620.74 | -7.69 | 0.09 | 12.78 | Mar 2026 |
| Strides Pharma Science Ltd | 1,235.10 | 11,384.25 | 41.04 | 0.07 | 17.97 | Mar 2026 |
| Viyash Scientific Ltd | 251.65 | 11,113.56 | 26.72 | 0.12 | 41.62 | Mar 2026 |
| Blue Jet Healthcare Ltd | 579.65 | 10,971.37 | -15.17 | 0.17 | 46.70 | Mar 2026 |
| Procter & Gamble Health Ltd | 5,503.50 | 9,135.47 | -12.16 | 0.08 | 25.61 | Mar 2026 |
| Aarti Pharmalabs Ltd | 846.45 | 7,675.59 | -5.98 | - | 36.00 | Mar 2026 |
| Sanofi India Ltd | 3,077.30 | 7,087.02 | -38.91 | 0.08 | 21.89 | Dec 2025 |
| Senores Pharmaceuticals Ltd | 1,395.10 | 6,424.94 | 94.81 | 0.10 | 48.96 | Mar 2025 |
| Jeena Sikho Lifecare Ltd | 508.10 | 6,315.72 | -38.12 | 0.11 | 26.75 | Mar 2026 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 21, 2026Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited - Press Release
Sep 15, 2026Aurobindo Pharma Limited has informed the Exchange regarding a press release dated September 15, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg".
Announcement under Regulation 30 (LODR)-Acquisition
Sep 12, 2026Intimation of subscription of 10000 shares of USD 100 each of A1 Biochem USA Inc by A1 Biochem Labs (India) Private Limited a step down subsidiary of the Company.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 11, 2026Intimation of investor / analyst meet scheduled on 18.09.2026.
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 11, 2026Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited - Copy of Newspaper Publication
Sep 03, 2026Aurobindo Pharma Limited has submitted copy of Newspaper Publications.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 03, 2026Submission of notice published in newspapers.
Announcement under Regulation 30 (LODR)-Acquisition
Sep 01, 2026Intimation of incorporation of a new wholly owned subsidiary by the name of Ávogent Lifesciences Private Limited by Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
Aurobindo Pharma Limited - Acquisition
Sep 01, 2026AUROPHARMA: Aurobindo Pharma Limited has informed the Exchange about incorporation of a new wholly owned subsidiary by the name of Avogent Lifesciences Private Limited in India by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Aug 31, 2026Submission of Press Release.
Aurobindo Pharma Limited - Press Release
Aug 31, 2026Aurobindo Pharma Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Lannett Company LLC, a wholly owned step down subsidiary of the Company announces launch of generic version of Advair Diskus® in the US".
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Aug 28, 2026Submission of Voting Results and Scrutinizers Report of 39th AGM of the Company held on August 27 2026.
Aurobindo Pharma Limited - Shareholders meeting
Aug 28, 2026Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Aug 27, 2026Submission of proceedings of 39th Annual General Meeting of the Company held on 27th August 2026.
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Aug 25, 2026Aurobindo Pharma Limited has informed the Exchange about Schedule of meet held on September 1-2, 2026 in Hong Kong
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Aug 25, 2026Intimation of Investor/ Analyst meet scheduled on September 1 2026.
Completion Of US FDA Inspection At Lannett Company LLC A Wholly Owned Subsidiary Of Aurobindo Pharma
Aug 24, 2026Intimation of completion of US FDA inspection at Lannett Company LLC. a wholly owned subsidiary of Aurobindo Pharma USA Inc.
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-08-05 | Quarterly Results | |
| 2026-05-21 | Audited Results | |
| 2026-04-06 | Buy Back of Shares | |
| 2026-02-09 | Quarterly Results | |
| 2025-11-05 | Quarterly Results | |
| 2025-08-04 | Quarterly Results & Interim Dividend | |
| 2025-05-26 | Audited Results | |
| 2025-02-06 | Quarterly Results | |
| 2024-11-09 | Quarterly Results | |
| 2024-08-10 | Quarterly Results | |
| 2024-07-18 | Buy Back of Shares | To consider buyback for equity shares |
| 2024-05-25 | Audited Results | |
| 2024-02-10 | Quarterly Results & Interim Dividend | |
| 2023-11-09 | Quarterly Results & Interim Dividend | |
| 2023-08-12 | Quarterly Results | |
| 2023-05-27 | Audited Results | |
| 2023-02-09 | Quarterly Results & Interim Dividend | |
| 2022-11-12 | Quarterly Results | |
| 2022-08-11 | Quarterly Results | |
| 2022-05-30 | Audited Results & 4th Interim Dividend | |
| 2022-02-09 | Quarterly Results & 3rd Interim Dividend | |
| 2021-11-08 | Quarterly Results & 2nd Interim Dividend | |
| 2021-08-12 | Quarterly Results & Interim Dividend | |
| 2021-05-31 | Audited Results | |
| 2021-02-10 | Quarterly Results & Interim Dividend | |
| 2020-11-11 | Quarterly Results & Interim Dividend | |
| 2020-08-12 | Quarterly Results & Interim Dividend | |
| 2020-06-03 | Audited Results | |
| 2020-02-06 | Quarterly Results & Interim Dividend | |
| 2019-11-12 | Quarterly Results & Interim Dividend | |
| 2019-08-07 | Quarterly Results | |
| 2019-05-28 | Audited Results | |
| 2019-02-07 | Quarterly Results & 2nd Interim Dividend | |
| 2018-11-12 | Quarterly Results & Interim Dividend | |
| 2018-08-09 | Unaudited Financial Results | |
| 2018-05-28 | Audited Results | |
| 2018-02-07 | Quarterly Results & 2nd Interim Dividend | |
| 2017-11-09 | Quarterly Results & Interim Dividend | |
| 2017-08-09 | Quarterly Results | |
| 2017-05-29 | Audited Results & Dividend | |
| 2017-02-09 | Quarterly Results | |
| 2016-11-14 | Quarterly Results & Interim Dividend | |
| 2016-08-23 | Quarterly Results | |
| 2016-05-30 | Audited Results & Dividend | Appointed Mr. B. Adi Reddy as the Company Secretary & Compliance Officer of the Company with effect from June 01, 2016. |
| 2016-02-09 | Quarterly Results & 3rd Interim Dividend | |
| 2015-11-06 | Raising of Funds | Raising of funds through issue of securities. |
| 2015-08-12 | Quarterly Results & Interim Dividend | |
| 2015-05-28 | Audited Results & Dividend | To considered and recommended for issue of ONE bonus equity share for every ONE equity share held as on a Record Date to be determined. |
| 2015-02-04 | Quarterly Results & 2nd Interim Dividend | |
| 2014-11-25 | To consider raising of funds | Inter alia, consider raising of funds through issue of securities. |
| 2014-11-06 | Quarterly Results | |
| 2014-08-07 | Interim Dividend | |
| 2014-05-30 | Audited Results & Dividend | Final Dividend & Second Interim Dividend |
| 2014-02-06 | Quarterly Results | |
| 2013-11-07 | Quarterly Results & Interim Dividend | |
| 2013-08-09 | Quarterly Results | |
| 2013-05-30 | Audited Results & Final Dividend | |
| 2013-02-07 | Quarterly Results & Interim Dividend | |
| 2012-11-09 | Quarterly Results | |
| 2012-08-07 | Quarterly Results | |
| 2012-05-29 | Audited Results & Dividend | |
| 2012-02-13 | Quarterly Results | (Revised) |
| 2012-01-18 | Appointment of Additional Director | The Board has appointed Dr. C Channa Reddy as an Additional Director of the Company, He will function as a Non Executive, Independent Director of the Company. |
| 2011-11-08 | Quarterly Results | |
| 2011-08-06 | Quarterly Results | |
| 2011-05-09 | Audited Results & Final Dividend | |
| 2011-02-05 | Quarterly Results | |
| 2010-11-03 | Interim Dividend & Stock split | The Board has approved the sub-division of Equity Shares of the face value of Rs. 5/- each in the Company into Equity Shares of the face value of Re. 1/- each. |
| 2010-08-05 | Quarterly Results | |
| 2010-05-29 | Audited Results & Final Dividend | |
| 2010-01-30 | Quarterly Results & Interim Dividend | The Board has approved payment of an Interim Dividend @ 60% i.e. Rs. 3/- per Equity Share of Rs. 5/- each to the members of the Company for the Current Financial Year 2009-2010. |
| 2009-11-12 | Audited Results, Dividend & Others | To consider the draft of Scheme of Amalgamation for the Merger of Trident Life Sciences Ltd being WoS of the Co., with itself & all the assets & liabilities of Trident shall be transfered. |
| 2009-10-30 | Quarterly Results | |
| 2009-08-14 | Acquisition of Stake | The Board has approved the proposal to acquire 100% stake of Trident Life Sciences Ltd, ("TLSL") subject to suitable agreements being executed between the parties for the same. |
| 2009-07-31 | Quarterly Results | |
| 2009-04-30 | Quarterly Results | |
| 2009-03-31 | Scheme of Arrangement | To approve the SoA, which provides the followings 1. Utilization of the Capital Redemption Reserve Account of Rs 90.0 million outstanding as on March 31, 2008 & 2. The gains arising on the buyback. |
| 2009-01-30 | Quarterly Results & Interim Dividend | |
| 2008-10-31 | Quarterly Results | |
| 2008-07-30 | Quarterly Results | |
| 2008-06-18 | Audited Results & Dividend | |
| 2008-01-30 | Quarterly Results | |
| 2007-10-31 | Quarterly Results | |
| 2007-07-31 | Quarterly Results | |
| 2007-06-30 | Audited Results & Dividend | |
| 2007-01-31 | Quarterly Results | |
| 2006-12-15 | Merger & ESOP | Inter alia, to consider the proposal for merger of APL Life Sciences Ltd & Senor Organics Pvt Ltd, the wholly owned subsidiary Companies of the Company, with itself. |
| 2006-11-14 | To acquire M/s. Senor Organics | To acquire M/s. Senor Organics Pvt Ltd, a profit making, small size pharma Company based at Hyderabad. |
| 2006-10-30 | Quarterly Results | |
| 2006-07-31 | Quarterly Results | |
| 2006-06-27 | Accounts & Dividend | |
| 2006-04-01 | To consider issue of FCCBs | To consider a proposal for issue of Foreign Currency Convertible Bonds (FCCBs) or other equity or equity linked securities in the overseas markets. |
| 2005-10-31 | Quarterly Results | |
| 2005-07-30 | Quarterly Results | |
| 2005-06-30 | Accounts, Dividend & Others | To consider a proposal for issue of Foreign Currency Convertible Bonds or such other similar securities in the Overseas markets. |
| 2005-01-15 | Quarterly Results | |
| 2004-10-29 | Quarterly Results | |
| 2004-07-31 | Quarterly Results | |
| 2004-06-02 | Dividend & Accounts | |
| 2004-02-18 | Others | To consider the allotment of equity shares of Rs 5/- each of the company to Merlion India Fund Ltd & also to appoint the nominee of Merlion on the Board of Directors of the company |
| 2004-01-31 | Quarterly Results | |
| 2003-11-29 | Others | To issue further shares of the company on private placement/preferential allotment basis. |
| 2003-10-31 | Quarterly Results | |
| 2003-08-09 | Sub Division of Equity shares | |
| 2003-07-31 | Quarterly Results | |
| 2003-06-30 | Accounts & Dividend | |
| 2003-01-31 | Quarterly Results | |
| 2002-11-15 | Others | Amalgamation of Ranit Pharma Ltd. and Calac Pvt. Ltd. with the company |
| 2002-10-31 | Quarterly Results & Half Yearly Results | |
| 2002-09-27 | Others | Issue of equity shares on conversion of share warrants which were issued to promoters/directors and Templeton STrategic Emerging Markets Fund LDC |
| 2002-06-30 | Accounts & Dividend | |
| 2002-04-14 | Others | Allotment of 10,00,000 equity shares & 10,00,000 Warrants to Templeton Emerging Markets Funds LDC. |
| 2002-03-27 | Others | To allot further equity shares/warrants to the promoters to the extent of receipt of subscriptions from them pursuant to the Special Resolution passed in the EGM held on 15-1-2002. |
| 2002-03-11 | Revocation of Interim Dividend | To consider the Revocation of Interim Dividend declared for the financial year 2001-2002. |
| 2002-03-08 | Interim Dividend | |
| 2002-01-31 | Quarterly Results | |
| 2001-12-14 | Private Placement | To issue further shares, convertible debentures or share warrants or such other instruments as the Board think fit, on private placement basis. (Revised) |
| 2001-10-31 | Quarterly Results | |
| 2001-07-31 | Quarterly Results | |
| 2001-06-29 | Accounts & Dividend | |
| 2001-01-31 | Quarterly Results | |
| 2000-10-31 | Amalgamation & Quarterly Results | amalgamation of Sri Chakra Remedies Ltd. with the company and Quarterly Results |
| 2000-08-28 | Preferential Allotment & Right Issue of Eq. Shares | |
| 2000-07-31 | Quarterly Results | |
| 2000-05-27 | Accounts | |
| 2000-03-27 | Interim dividend | |
| 2000-01-22 | Quarterly Results & Bonus issue | |
| 1999-10-30 | Quarterly Results | |
| 1999-07-21 | Quarterly Results | |
| 1999-05-15 | Accounts, Dividend | |
| 1999-01-30 | Quarterly Results | |
| 1998-10-27 | Quarterly Results | |
| 1997-12-26 | Private Placement | |
| 1997-11-15 | Half Yearly Results |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2025-08-08 | 4 | INTERIM | 2025-08-08 | Equity Share |
| 2024-02-20 | 1.5 | INTERIM | 2024-02-20 | Equity Share |
| 2023-11-20 | 3 | INTERIM | 2023-11-20 | Equity Share |
| 2023-02-17 | 3 | INTERIM | 2023-02-17 | Equity Share |
| 2022-06-06 | 4.5 | INTERIM | 2022-06-07 | Equity Share |
| 2022-02-18 | 1.5 | INTERIM | 2022-02-21 | Equity Share |
| 2021-11-17 | 1.5 | INTERIM | 2021-11-18 | Equity Share |
| 2021-08-27 | 1.5 | INTERIM | 2021-08-30 | Equity Share |
| 2021-02-22 | 1.5 | INTERIM | 2021-02-23 | Equity Share |
| 2020-11-23 | 1.25 | INTERIM | 2020-11-24 | Equity Share |
| 2020-08-21 | 1.25 | INTERIM | Equity Share | |
| 2020-02-17 | 1.75 | INTERIM | 2020-02-18 | Equity Share |
| 2019-11-21 | 1.25 | INTERIM | 2019-11-23 | Equity Share |
| 2019-02-15 | 1.25 | INTERIM | 2019-02-19 | Equity Share |
| 2018-11-20 | 1.25 | INTERIM | 2018-11-22 | Equity Share |
| 2018-02-20 | 1 | INTERIM | 2018-02-21 | Equity Share |
| 2017-11-21 | 1.5 | INTERIM | 2017-11-22 | Equity Share |
| 2017-06-08 | 1.25 | INTERIM | 2017-06-09 | Equity Share |
| 2016-11-24 | 1.25 | INTERIM | 2016-11-25 | Equity Share |
| 2016-06-09 | 0.7 | INTERIM | 2016-06-10 | Equity Share |
| 2016-02-18 | 0.7 | INTERIM | 2016-02-22 | Equity Share |
| 2015-11-19 | 0.6 | INTERIM | 2015-11-20 | Equity Share |
| 2015-08-21 | 0.5 | INTERIM | Equity Share | |
| 2015-06-08 | 1 | INTERIM | 2015-06-09 | Equity Share |
| 2015-02-16 | 2 | INTERIM | 2015-02-18 | Equity Share |
| 2014-08-13 | 1.5 | INTERIM | Equity Share | |
| 2014-06-11 | 1.75 | INTERIM | 2014-06-12 | Equity Share |
| 2013-11-19 | 1.25 | INTERIM | 2013-11-20 | Equity Share |
| 2013-07-30 | 0.5 | FINAL | Equity Share | |
| 2013-02-18 | 1 | INTERIM | 2013-02-20 | Equity Share |
| 2012-07-30 | 1 | FINAL | Equity Share | |
| 2011-07-20 | 1 | FINAL | Equity Share | |
| 2010-11-11 | 5 | INTERIM | 2010-11-12 | Equity Share |
| 2010-09-13 | 2 | FINAL | Equity Share | |
| 2010-02-05 | 3 | INTERIM | 2010-02-08 | Equity Share |
| 2009-12-16 | 1.5 | FINAL | Equity Share | |
| 2009-02-05 | 3 | INTERIM | 2009-02-06 | Equity Share |
| 2008-08-11 | 3.25 | FINAL | Equity Share | |
| 2007-09-14 | 2.5 | FINAL | Equity Share | |
| 2006-09-08 | 1.5 | FINAL | Equity Share | |
| 2005-09-20 | 0.5 | FINAL | Equity Share | |
| 2004-07-22 | 2.25 | FINAL | Equity Share | |
| 2003-09-08 | 3.5 | FINAL | Equity Share | |
| 2002-09-19 | 3 | FINAL | Equity Share |
| Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
| 2011-02-10 | 5 | 1 | 2011-02-11 |
| 2003-10-23 | 10 | 5 | 2003-10-31 |
No Data Found
| Event Date | Event |
|---|---|
| Jul 20, 2015 | Bonus |
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Goldman Sachs Bank Europese - Odi | Block | 2025-10-16 |
Purchase |
1,107.00 | 106,228 | NSE |
| Goldman Sachs (Singapore) Pte.- Odi | Block | 2025-10-16 |
Sell |
1,107.00 | 106,228 | NSE |
| Societe Generale | Block | 2024-01-25 |
Purchase |
1,160.10 | 1,484,323 | BSE |
| Marshall Wace Investment Strategies - Eureka Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 106,480 | BSE |
| Marshall Wace Investment Strategies Eureka Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 53,641 | NSE |
| Marshall Wace Investment Strategies Tops Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 44,921 | NSE |
| Marshall Wace Investment Strategiesgtops Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 27,571 | BSE |
| Marshall Wace Investment Strategies - Systematic Alpha Plus Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 15,950 | BSE |
| Marshall Wace Investment Strategies Market Neutral Tops Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 8,134 | NSE |
| Marshall Wace Investment Strategies Systematic Alpha Plus Fund | Block | 2024-01-25 |
Purchase |
1,160.10 | 862 | NSE |
| Bnp Paribas Arbitrage | Block | 2024-01-25 |
Sell |
1,160.10 | 1,484,323 | BSE |
| Bnp Paribas Arbitrage | Block | 2024-01-25 |
Sell |
1,160.10 | 150,001 | BSE |
| Societe Generale | Block | 2024-01-25 |
Sell |
1,160.10 | 107,558 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-14 |
Purchase |
489.30 | 297,308 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-14 |
Sell |
489.30 | 297,308 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-03 |
Purchase |
557.30 | 297,309 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-03 |
Sell |
557.30 | 297,309 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-25 |
Purchase |
524.50 | 277,213 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-25 |
Sell |
524.50 | 277,213 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-17 |
Purchase |
514.05 | 435,602 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-17 |
Sell |
514.05 | 435,602 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-11 |
Purchase |
535.45 | 319,465 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-11 |
Sell |
535.45 | 319,465 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-03 |
Purchase |
510.60 | 319,654 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-03 |
Sell |
510.60 | 319,654 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-09-19 |
Purchase |
533.10 | 217,295 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-09-19 |
Sell |
533.10 | 217,295 | BSE |
| Ishares Msci India Etf | Block | 2022-08-08 |
Purchase |
568.65 | 311,433 | NSE |
| Ishares India Index Mauritius Company | Block | 2022-08-08 |
Sell |
568.65 | 311,433 | NSE |
| Ishares Msci India Etf | Block | 2022-07-25 |
Purchase |
550.95 | 311,432 | NSE |
| Ishares India Index Mauritius Company | Block | 2022-07-25 |
Sell |
550.95 | 311,432 | NSE |
| Ishares Msci India Etf | Block | 2022-07-18 |
Purchase |
548.75 | 313,304 | BSE |
| Ishares India Index Mauritius Company | Block | 2022-07-18 |
Sell |
548.75 | 313,304 | BSE |
| Ishares Core Msci Total International Stock Etf | Block | 2022-05-04 |
Purchase |
642.50 | 354,384 | BSE |
| Ishares Core Total International Stock Mauritius Co | Block | 2022-05-04 |
Sell |
642.50 | 354,384 | BSE |
| Pzena Value Funds Plc/Pzena Emerging Markets Value Fund | Block | 2022-03-11 |
Purchase |
630.40 | 250,294 | NSE |
| Pzena Value Funds Plc/Pzena Emerging Markets Value Fund | Block | 2022-03-11 |
Sell |
630.40 | 250,294 | NSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-20 |
Purchase |
712.55 | 264,506 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-20 |
Sell |
712.55 | 264,506 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-11 |
Purchase |
714.75 | 264,506 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-11 |
Sell |
714.75 | 264,506 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-04 |
Purchase |
717.30 | 271,948 | NSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-04 |
Sell |
717.30 | 271,948 | NSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-09-23 |
Purchase |
731.10 | 269,231 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-09-23 |
Sell |
731.10 | 269,231 | BSE |
| Ishares Msci All Country Asia Ex Japan Etf | Block | 2021-07-19 |
Purchase |
975.55 | 125,832 | BSE |
| Ishares All Country Asia Ex Japan Mauritius Co | Block | 2021-07-19 |
Sell |
975.55 | 125,832 | BSE |
| Ishares Msci All Country Asia Ex Japan Etf | Block | 2021-07-12 |
Purchase |
948.70 | 126,581 | BSE |
| Ishares All Country Asia Ex Japan Mauritius Co | Block | 2021-07-12 |
Sell |
948.70 | 126,581 | BSE |
| The Mtbj Ltd. As Trst For Government Pension Investment Fund Mtbj400045849 | Block | 2021-04-08 |
Purchase |
905.60 | 131,889 | BSE |
| The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794 | Block | 2021-04-08 |
Sell |
905.60 | 131,889 | BSE |
| Jhunjhunwala Rakesh | Block | 2021-04-07 |
Purchase |
905.65 | 1,625,000 | NSE |
| Rare Enterprises | Block | 2021-04-07 |
Sell |
905.65 | 1,625,000 | NSE |
| Powershares India Portfolio | Block | 2019-03-25 |
Purchase |
768.30 | 181,220 | NSE |
| Powershares Mauritius (Pinspv) (679038) | Block | 2019-03-25 |
Sell |
768.30 | 181,220 | NSE |
| Hema Govindarajan | Block | 2017-03-28 |
Purchase |
682.00 | 200,000 | NSE |
| Govindarajan Narayanan | Block | 2017-03-28 |
Sell |
682.00 | 200,000 | NSE |
| Hema Govindarajan | Block | 2017-03-21 |
Purchase |
699.00 | 530,000 | NSE |
| Govindarajan Narayanan | Block | 2017-03-21 |
Sell |
699.00 | 530,000 | NSE |
| Rajeswari Kambam | Block | 2017-03-03 |
Purchase |
672.00 | 200,000 | NSE |
| Sivakumaran Meenakshi | Block | 2017-03-03 |
Sell |
672.00 | 200,000 | NSE |
| Suneela Rani Penaka | Bulk | 2016-10-07 |
Sell |
849.30 | 8,660,510 | NSE |
| The Vanguard Group Inc A/C Vanguard Emerg. Mkts Stock Inde | Bulk | 2014-09-19 |
Purchase |
875.94 | 2,360,231 | NSE |
| Abu Dhabi Investment Authoruty - Gulab | Bulk | 2014-05-30 |
Purchase |
670.51 | 1,475,687 | NSE |
| M/S Morgan Stanley Asia Singapore Pte | Bulk | 2014-05-30 |
Sell |
669.92 | 1,732,500 | NSE |
| Macquarie Bank Limited | Bulk | 2013-08-29 |
Sell |
180.97 | 1,940,000 | NSE |
| Reliance Capital Trustee Co. Ltd A/C Regular Saving Fund-Rel | Bulk | 2011-02-24 |
Purchase |
172.99 | 1,500,000 | NSE |
| Hsbc Global Investment Fund A/C Indian Equity Fund | Bulk | 2011-02-24 |
Sell |
173.03 | 2,353,228 | NSE |
| Deutsche Securities Mauritius Ltd. | Bulk | 2010-08-26 |
Purchase |
1,037.53 | 375,750 | NSE |
| Merrill Lynch Capital Markets Espana S.A Sv Fccb | Bulk | 2010-08-26 |
Sell |
1,035.66 | 703,898 | NSE |
| Deutsche Securities Mauritius Limited | Bulk | 2010-01-28 |
Purchase |
851.50 | 597,541 | NSE |
| Barclays Capital Mauritius Ltd | Bulk | 2010-01-28 |
Sell |
851.50 | 597,541 | NSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| M.Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 95,000 | 893,000 | SAST Reg31 | Release | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 400,000 | 3,077,500 | SAST Reg31 | Creation | |
| Mr. M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 595,000 | 298,000 | SAST Reg31 | Release | |
| M/S P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 700,000 | 16,500,000 | SAST Reg31 | Creation | |
| Mr.K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 450,000 | 4,791,297 | SAST Reg31 | Release | |
| Mrs.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 15,500,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 210,000 | 508,000 | SAST Reg31 | Creation | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 3,000,000 | 2,600,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 1,600,000 | 4,200,000 | SAST Reg31 | Creation | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 111,000 | 2,966,500 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 50,000 | 458,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 120,000 | 578,000 | SAST Reg31 | Creation | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 20,000 | 598,000 | SAST Reg31 | Creation | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 360,000 | 958,000 | SAST Reg31 | Creation | |
| Mr. M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 248,000 | 710,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 760,000 | 4,960,000 | SAST Reg31 | Creation | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 2,291,000 | 13,209,000 | SAST Reg31 | Release | |
| Mrs.P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,500,000 | 11,709,000 | SAST Reg31 | Release | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 60,500 | 2,906,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 3,960,000 | SAST Reg31 | Release | |
| Mr.Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 30,000 | 90,000 | SAST Reg31 | Release | |
| M.Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 120,000 | 830,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 5,041,297 | SAST Reg31 | Creation | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 180,000 | 11,889,000 | SAST Reg31 | Creation | |
| Mrs Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 390,000 | 2,516,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 315,000 | 2,831,000 | SAST Reg31 | Creation | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 200,000 | 12,089,000 | SAST Reg31 | Creation | |
| Mrs.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 400,000 | 11,689,000 | SAST Reg31 | Release | |
| Mrs Kambam Spoorthy | Promoter |
Pledge |
2024-12-24 | 550,000 | 2,281,000 | SAST Reg31 | Release | |
| Mr. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 10,000 | 2,271,000 | SAST Reg31 | Release | |
| Mr.Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 25,000 | 115,000 | SAST Reg31 | Creation | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 70,000 | 900,000 | SAST Reg31 | Creation | |
| Mrs.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,970,000 | 9,719,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 80,000 | 980,000 | SAST Reg31 | Creation | |
| Mr. K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 210,000 | 5,251,297 | SAST Reg31 | Creation | |
| P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,600,000 | 8,119,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 724,000 | 4,527,297 | SAST Reg31 | Release | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,200,000 | 6,919,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 65,000 | 2,206,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 60,000 | 920,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 140,000 | 780,000 | SAST Reg31 | Release | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 100,000 | 981,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 1,125,000 | 1,081,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 313,500 | 667,500 | SAST Reg31 | Release | |
| Mrs.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 400,000 | 6,519,000 | SAST Reg31 | Release | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 1,500 | 666,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 300,000 | 656,000 | SAST Reg31 | Release | |
| Mr.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 100,000 | 6,619,000 | SAST Reg31 | Creation | |
| Mr.K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 350,000 | 4,877,297 | SAST Reg31 | Creation | |
| Mr.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 500,000 | 6,119,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 2,257,297 | 2,620,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 2,360,000 | 0 | SAST Reg31 | Release | |
| Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 3,420 | 118,420 | SAST Reg31 | Creation | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 2,000,000 | 2,000,000 | SAST Reg31 | Creation | |
| P V Ramprasad Reddy | Promoter |
Pledge |
2024-12-24 | 2,000,000 | 0 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 500,000 | 2,100,000 | SAST Reg31 | Release | |
| Mr.P V Ramprasad Reddy | Promoter |
Pledge |
2024-12-24 | 2,000,000 | 0 | SAST Reg31 | Release | |
| Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 3,420 | 115,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 300,000 | 2,300,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 90,000 | 2,710,000 | SAST Reg31 | Creation | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 900,000 | 5,219,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 300,000 | 1,800,000 | SAST Reg31 | Release | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 175,000 | 5,044,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 339,000 | 2,371,000 | SAST Reg31 | Release | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 229,000 | 2,142,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 1,100,000 | 700,000 | SAST Reg31 | Release | |
| P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,250,000 | 3,794,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 125,000 | 2,017,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 329,000 | 1,029,000 | SAST Reg31 | Creation | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 200,000 | 866,000 | SAST Reg31 | Creation | |
| P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 900,000 | 2,894,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 12,000 | 2,029,000 | SAST Reg31 | Creation | |
| K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 25,000 | 2,054,000 | SAST Reg31 | Creation | |
| Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 42,000 | 824,000 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 10,000 | 770,000 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 10,000 | 760,000 | SAST Reg31 | Release | |
| Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 45,000 | 779,000 | SAST Reg31 | Release | |
| Mrs. K. Kirthi Reddy | Promoter |
Pledge |
2024-12-24 | 150,000 | 150,000 | SAST Reg31 | Creation | |
| Mrs. K. Kirthi Reddy | Promoter |
Pledge |
2024-12-24 | 75,000 | 75,000 | SAST Reg31 | Release | |
| Mr P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 180,000 | 2,714,000 | SAST Reg31 | Release | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 110,000 | 650,000 | SAST Reg31 | Release | |
| K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 125,000 | 1,929,000 | SAST Reg31 | Release | |
| P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 125,000 | 2,589,000 | SAST Reg31 | Release | |
| P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 125,000 | 2,589,000 | SAST Reg31 | Release | |
| Mr. M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 750,000 | SAST Reg31 | Creation | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 485,000 | 1,444,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 147,310 | 1,296,690 | SAST Reg31 | Release | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 400,000 | 2,189,000 | SAST Reg31 | Release | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 90,000 | 2,099,000 | SAST Reg31 | Release | |
| K Spoorthi Reddy | Promoter |
Pledge |
2024-12-24 | 80,000 | 859,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 690 | 1,296,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 100,000 | 2,200,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 1,058,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 4,000,000 | 400,000 | SAST Reg31 | Release | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 750,000 | 2,468,000 | SAST Reg31 | Creation | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 1,200,000 | 2,998,000 | SAST Reg31 | Release | |
| Mr. M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 160,000 | 1,340,000 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 550,000 | 790,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 125,000 | 2,705,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 358,000 | 2,347,000 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 2,200,000 | 4,400,000 | SAST Reg31 | Creation | |
| Mr. K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 1,284,000 | 2,580,000 | SAST Reg31 | Creation | |
| Mr. M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 750,000 | 1,500,000 | SAST Reg31 | Creation | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 859,000 | 1,718,000 | SAST Reg31 | Creation | |
| Mr. Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 115,000 | 230,000 | SAST Reg31 | Creation | |
| Axis Clinicals Ltd | Promoter |
Pledge |
2024-12-24 | 1,029,000 | 2,058,000 | SAST Reg31 | Creation | |
| Mrs. P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 2,099,000 | 4,198,000 | SAST Reg31 | Creation | |
| Mrs. K Kirthi Reddy | Promoter |
Pledge |
2024-12-24 | 75,000 | 150,000 | SAST Reg31 | Creation | |
| Mrs. K. Rajeswari | Promoter |
Pledge |
2024-12-24 | 200,000 | 200,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 50,000 | 2,397,000 | SAST Reg31 | Creation | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 300,000 | 3,298,000 | SAST Reg31 | Creation | |
| Mr Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 130,000 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 1,600,000 | 797,000 | SAST Reg31 | Release | |
| Mrs.P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 300,000 | 3,598,000 | SAST Reg31 | Creation | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 130,000 | 920,000 | SAST Reg31 | Creation | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 35,000 | 3,633,000 | SAST Reg31 | Creation | |
| Mr. K Rajeswari | Promoter |
Pledge |
2024-12-24 | 50,000 | 250,000 | SAST Reg31 | Creation | |
| Mrs. K. Rajeswari | Promoter |
Pledge |
2024-12-24 | 50,000 | 200,000 | SAST Reg31 | Release | |
| Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 170,000 | 300,000 | SAST Reg31 | Creation | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 150,000 | 1,070,000 | SAST Reg31 | Creation | |
| Mr.K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 275,000 | 1,072,000 | SAST Reg31 | Creation | |
| Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 128,400 | 171,600 | SAST Reg31 | Release | |
| Trident Chemphar Limited | Promoter |
Pledge |
2024-12-24 | 400,000 | 0 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,170,000 | SAST Reg31 | Creation | |
| M. Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 80,000 | 1,090,000 | SAST Reg31 | Release | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 400,000 | 3,233,000 | SAST Reg31 | Release | |
| Mrs. P. Suneela Rani | Promoter |
Pledge |
2024-12-24 | 400,000 | 2,833,000 | SAST Reg31 | Release | |
| M. Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,190,000 | SAST Reg31 | Creation | |
| K . Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 200,000 | 1,272,000 | SAST Reg31 | Creation | |
| Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 958,000 | 1,510,000 | SAST Reg31 | Release | |
| Kambam Nityanand Reddy | Promoter |
Pledge |
2024-12-24 | 130,000 | 1,142,000 | SAST Reg31 | Release | |
| Mrs K. Kirthi Reddy | Promoter |
Pledge |
2024-12-24 | 150,000 | 0 | SAST Reg31 | Release | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 692,000 | 450,000 | SAST Reg31 | Release | |
| Mrs P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 833,000 | 2,000,000 | SAST Reg31 | Release | |
| K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 450,000 | 0 | SAST Reg31 | Release | |
| P Suneela Rani | Promoter |
Pledge |
2024-12-24 | 2,000,000 | 0 | SAST Reg31 | Release | |
| Mr. Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 120,000 | 291,600 | SAST Reg31 | Creation | |
| Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 1,600 | 290,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 400,000 | 658,000 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 140,000 | 1,050,000 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 140,000 | 1,050,000 | SAST Reg31 | Release | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 650,000 | 650,000 | SAST Reg31 | Creation | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 300,000 | 950,000 | SAST Reg31 | Creation | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 475,000 | 1,425,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 300,000 | 1,725,000 | SAST Reg31 | Creation | |
| Amit Sheth | Promoter |
2024-12-24 | 504,000 | 661,000 | SAST Reg31 | Release | ||
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 1,975,000 | SAST Reg31 | Creation | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 150,000 | 2,125,000 | SAST Reg31 | Creation | |
| Mr.Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 120,000 | 170,000 | SAST Reg31 | Release | |
| Mr K.Nityananda Reddy, | Promoter |
Pledge |
2024-12-24 | 300,000 | 2,425,000 | SAST Reg31 | Creation | |
| Mr. M. Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,150,000 | SAST Reg31 | Creation | |
| Mr. K. Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 140,000 | 2,565,000 | SAST Reg31 | Creation | |
| Mr. M. Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,250,000 | SAST Reg31 | Creation | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 750,000 | 2,260,000 | SAST Reg31 | Creation | |
| Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 750,000 | 1,510,000 | SAST Reg31 | Release | |
| K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 350,000 | 2,915,000 | SAST Reg31 | Creation | |
| Mr. K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 300,000 | 3,215,000 | SAST Reg31 | Creation | |
| Axis Clinicals Ltd Trident Chemphar Ltd Rrr Sons Advisors Pvt Ltd (Jointly Holding) | Promoter |
Pledge |
2024-12-24 | 2,100,000 | 2,100,000 | SAST Reg31 | Creation | |
| K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 500,000 | 3,715,000 | SAST Reg31 | Creation | |
| Axis Clinicals Limited. Trident Chemphar Ltd. Rpr Sons Advisors Pvt. Ltd. (Jointly Holding) | Promoter |
Pledge |
2024-12-24 | 1,000,000 | 3,100,000 | SAST Reg31 | Creation | |
| Mr. K. Nityananda Reddy | Promoter |
Pledge |
2024-12-24 | 225,000 | 3,940,000 | SAST Reg31 | Creation | |
| Mr. M. Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 1,500,000 | SAST Reg31 | Creation | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 1,500,000 | SAST Reg31 | Creation | |
| Mrs. Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 120,000 | 1,630,000 | SAST Reg31 | Creation | |
| Mr. K. Nityananda Reddy | Promoter |
Pledge |
2024-12-24 | 425,000 | 4,365,000 | SAST Reg31 | Creation | |
| K.Nityananda Reddy | Promoter |
Pledge |
2024-12-24 | 200,000 | 4,565,000 | SAST Reg31 | Creation | |
| Mrs.Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,730,000 | SAST Reg31 | Creation | |
| Mrs Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 200,000 | 1,930,000 | SAST Reg31 | Creation | |
| Mr. K. Nityananda Reddy | Promoter |
Pledge |
2024-12-24 | 450,000 | 5,015,000 | SAST Reg31 | Creation | |
| K Rajeswari | Promoter |
Pledge |
2024-12-24 | 200,000 | 400,000 | SAST Reg31 | Creation | |
| Mrs Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 800,000 | 2,730,000 | SAST Reg31 | Creation | |
| K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 785,000 | 5,800,000 | SAST Reg31 | Creation | |
| Mr K Nityananda Reddy | Promoter |
Pledge |
2024-12-24 | 200,000 | 6,000,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 180,000 | 6,430,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 6,250,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 170,000 | 6,600,000 | SAST Reg31 | Creation | |
| Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 2,870,000 | 5,600,000 | SAST Reg31 | Creation | |
| Mrs Kambam Spoorthi | Promoter |
Pledge |
2024-12-24 | 1,570,000 | 4,030,000 | SAST Reg31 | Release | |
| Mr M.Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 1,300,000 | 200,000 | SAST Reg31 | Release | |
| K Rajeswari | Promoter |
Pledge |
2024-12-24 | 200,000 | 200,000 | SAST Reg31 | Release | |
| Axis Clinicals Limited | Promoter |
Pledge |
2024-12-24 | 658,000 | 0 | SAST Reg31 | Release | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 400,000 | 600,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 7,250,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 300,000 | 8,000,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 200,000 | 7,700,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 400,000 | 7,000,000 | SAST Reg31 | Creation | |
| K Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 250,000 | 7,500,000 | SAST Reg31 | Creation | |
| Axis Clinicals Ltd | Promoter |
Pledge |
2024-12-24 | 658,000 | 658,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 450,000 | 8,750,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 325,000 | 9,350,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 275,000 | 9,025,000 | SAST Reg31 | Creation | |
| Mr.K.Nithyananda Reddy | Promoter |
Pledge |
2024-12-24 | 300,000 | 8,300,000 | SAST Reg31 | Creation | |
| M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 200,000 | 1,200,000 | SAST Reg31 | Creation | |
| Mr.M.Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 400,000 | 1,000,000 | SAST Reg31 | Creation | |
| Mr.M Sumanth Kumar Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 1,300,000 | SAST Reg31 | Creation | |
| Rpr Sons Advisors Private Limited P Suneela Rani Jointly Holding | Promoter |
Pledge |
2024-12-24 | 2,860,000 | 2,860,000 | SAST Reg31 | Creation | |
| Mr Kambam Prasad Reddy | Promoter |
Pledge |
2024-12-24 | 100,000 | 270,000 | SAST Reg31 | Creation | |
| Rpr Sons Advisors Pvt Ltd P.Suneela Rani Joint Holding | Promoter |
Pledge |
2024-12-24 | 4,200,000 | 7,060,000 | SAST Reg31 | Creation | |
| Rpr Sons Advisors Pvt Ltd P.Suneela Rani Joint Holding | Promoter |
Pledge |
2024-12-24 | 1,200,000 | 9,560,000 | SAST Reg31 | Creation | |
| Rpr Sons Advisors Pvt Ltd P.Suneela Rani Joint Holding | Promoter |
Pledge |
2024-12-24 | 1,300,000 | 8,360,000 | SAST Reg31 | Creation | |
| Axis Clinicals, Trident Chemphar Ltd, Rpr Sons Advisors Pvt Ltd Jointly Holding | Promoter |
Pledge |
2024-12-24 | 3,090,000 | 10,000 | SAST Reg31 | Release |
About Aurobindo Pharma Ltd
Stock PE (TTM)
26.63
Promoter Holding
51.88%
Book Value
658.5312
ROCE
12.43%
ROE
9.93%
Aurobindo Pharma is a distinguished name in the pharmaceutical industry. It was incorporated in 1986, and its headquarters is located in Hyderabad. As of 31 December 2021, it reported a net income of Rs 604.73 crore. The prominent faces in Aurobindo Pharma management are—Mr K Raghunathan, Mr K Nityananda Reddy, Dr M. Sivakumaran, Mr P. V Ram Prasad Reddy, and a few more. Aurobindo Pharma’s valuation on the stock exchange is Rs 30,636 crore.
The company is listed on both the stock exchanges of India, that is NSE and BSE. It is traded under the symbol AURO PHARMA.
The company is primarily into the development, manufacturing, and supply of active pharmaceutical ingredients, generic pharmaceuticals, and branded speciality pharmaceuticals. Some key offerings in its product portfolio cater to/include antibiotics, central nervous system, anti-diabetics, gastroenterological, anti-retroviral, and cardiovascular. The company currently supplies its products to more than 150 countries. Its subsidiary company list includes Aurolife Pharma LLC, APL Healthcare, Auro Peptides Ltd, Auronext Pharma Pvt. Ltd. and a few more.
Now, if you dive into the company’s financials, you will find the following.
Aurobindo Pharma’s price-to-equity ratio or PE ratio (6.13) and price-to-book ratio or PB ratio (1.49) are better than the industry’s average. The same is the case with revenue and net income. Over the past five years, Aurobindo Pharma’s revenue and income have grown at an annual rate of 15.2% and 21.38%, respectively. For the same period, the industry’s average income and revenue growth rates were 6.94% and 8.25%, respectively. Aurobindo Pharma’s total liabilities declined by Rs 467.41 crore compared to the financial year 2020. Even after reducing the liabilities, the company cash flow statement shows a free cash flow of Rs 1455.11 crore in FY20-21.
On 20 May 2022, the Aurobindo Pharma share price on NSE closed at Rs 557.95. It was 6.71% higher than the previous day’s closing price. The last 52 weeks’ movement of Aurobindo Pharma Ltd.’s share price on the stock market saw a high of Rs 1,043.10 and a low of Rs 520.85. Investing in Aurobindo Pharma shares carries a low amount of risk since its price volatility is 1.95x that of the Nifty. The key names in its peers’ list are Cipla Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.
Aurobindo Pharma share price as on 22 Sep 2026 is Rs. 1713.4. Over the past 6 months, the Aurobindo Pharma share price has increased by 35.02% and in the last one year, it has increased by 51.78%. The 52-week low for Aurobindo Pharma share price was Rs. 1066.8 and 52-week high was Rs. 1738.9.
Registered Office
Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038
Tel No. 91-40-23736370
Email cs:aurobindo.com; investorgrievances:aurobindo.com
Registrars
Management
Non Executive Director
Independent Non Exe. Director
Non-Exec & Non-Independent Dir
Chairman & Independent Directo
Vice Chairman & M.D.
Independent Non Exe. Director
E D & Wholetime Director
Independent Non Exe. Director
Company Sec. & Compli. Officer
Non-Exec & Non-Independent Dir
Listing Info
524804
AUROPHARMA
INE406A01037
Aug
Aurobindo Pharma Ltd FAQs
You can buy Aurobindo Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aurobindo Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 21, 2026 03:55 PM the closing price of Aurobindo Pharma Ltd was Rs.1,713.40.
The latest PE ratio of Aurobindo Pharma Ltd as of Sep 21, 2026 03:55 PM is 26.63
The latest PB ratio of Aurobindo Pharma Ltd as of Sep 21, 2026 03:55 PM is 2.60
The 52-week high of Aurobindo Pharma Ltd share price is Rs. 1,738.90 while the 52-week low is Rs. 1,066.80
According to analyst recommendations, Aurobindo Pharma Ltd Share has a "Buy" rating for the long term.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 21, 2026 03:55 PM, the market cap of Aurobindo Pharma Ltd stood at Rs. 98,585.27 Cr.
Market Outlook
View all
16-06-2026 15:18:00
Navneet Munot on Inevitable India, Deep Tech, Artificial Intelligence and the Next Phase of Wealth Creation
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, an engaging Ask Me Anything session brought together investors and market participants for a conversation with Navneet ...
-202606161502166115397.jpg)
16-06-2026 15:04:00
India Investor Conference 2026 : India's Power Infrastructure Boom and Data Center Growth Opportunity
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, Kushal Desai, Chairman and Managing Director of APAR Industries, shared his perspective on the forces reshaping the global po...
16-06-2026 14:52:00
India Investor Conference 2026 - Deep dive into the Electronics Manufacturing Industry
ICICI Securities Ltd - INZ000183631 How India’s Electronics Manufacturing Industry Is Moving Beyond Assembly to Become a Global Design and Engineering Hub At the India Investor Conference 2026, ...
16-06-2026 01:01:00
India Investor Conference 2026 - Professor V. Kamakoti on Building a Technology Superpower Through Startups, Innovation and Deep Tech
ICICI Securities Ltd - INZ000183631 Speaking at the India Investor Conference 2026, Professor V. Kamakoti, Director, IIT Madras, shared his perspective on how academic institutions, industry leaders a...
